| scholarly article | Q13442814 |
| P50 | author | Udai Banerji | Q41195747 |
| P2093 | author name string | A Stewart | |
| P Thavasu | |||
| J S de Bono | |||
| P2860 | cites work | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 |
| Intratumor heterogeneity: evolution through space and time | Q24598678 | ||
| Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling | Q27851446 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors | Q27851678 | ||
| Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. | Q27851698 | ||
| Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | Q27851711 | ||
| Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background | Q27851716 | ||
| Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial | Q27851856 | ||
| Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models | Q28275413 | ||
| Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo | Q28476362 | ||
| Combinatorial drug therapy for cancer in the post-genomic era. | Q34287101 | ||
| Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies | Q34367804 | ||
| AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity | Q34511038 | ||
| Antitumor activity in RAS-driven tumors by blocking AKT and MEK. | Q35103514 | ||
| Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. | Q37281508 | ||
| Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways | Q38091054 | ||
| MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors | Q39355055 | ||
| In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. | Q39830937 | ||
| Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells | Q40005203 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma | Q42723115 | ||
| The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer | Q43152544 | ||
| Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. | Q45257167 | ||
| The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer | Q54535188 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 1504-1510 | |
| P577 | publication date | 2015-04-23 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors | |
| P478 | volume | 26 |
| Q38734451 | Combine and conquer: challenges for targeted therapy combinations in early phase trials. |
| Q38906990 | Exploiting receptor tyrosine kinase co-activation for cancer therapy |
| Q55708895 | Impact of Environmental Pollutant Cadmium on the Establishment of a Cancer Stem Cell Population in Breast and Hepatic Cancer. |
| Q37203121 | Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer |
| Q92915778 | Is phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway therapeutic target for esophageal adenocarcinoma |
| Q28072254 | Maximising the potential of AKT inhibitors as anti-cancer treatments |
| Q38748208 | Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. |
| Q88512529 | Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors |
| Q38708614 | Phosphoproteomics in translational research: a sarcoma perspective. |
| Q47760790 | Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168). |
| Q90357648 | Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy |
Search more.